The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing

Current Medical Research and Opinion

Volumn 20, Issue 8, 2004, Pages 1301-1307

  Sivri, Bulent ^a   Simsek, Ilkay ^b   Hulagu, Saadettin ^c   Kadayifci, Abdurrahman ^d   Tozun, Nurdan ^e   Akarsu, Mesut ^b   Uraz, Suleyman ^c   Savas, M Cemil ^d   Koruk, Mehmet ^d   Bozbas, Aysun ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

^d GAZIANTEP UNIVERSITY   (Turkey)

^e MARMARA UNIVERSITY   (Turkey)

Author keywords

Amoxicillin; Clarithromycin; Duodenal ulcer; Eradication; H. pylori; Pantoprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL DISCOMFORT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; EPIGASTRIC PAIN; ERADICATION THERAPY; FATIGUE; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRURITUS; RASH; SIDE EFFECT; STOMACH ACID SECRETION; ULCER HEALING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 4344568572     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004439     Document Type: Article

References (31)

1. Schepp W. Proton pump inhibitory therapy: then and now. Yale J Biol Med 1996;69:175-86
2. +)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol 1992;218:265-71
3. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-82
4. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987;28:1120-27
5. McIsaac RL, McCanless I, Summers K, Wood JR. Ranitidine and cimetidine in the healing of duodenal ulcer: meta-analysis of comparative clinical trials. Aliment Pharm Ther 1987;1:369-81
6. Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994;343:258-60
7. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000;38:243-70
8. Malfertheiner P, Megraud F, O'Morain C, et al.; European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80
9. Gurel S, Besisk F, Demir K, et al. After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. J Clin Gastroenterol 1999;28:241-44
10. Kadayifci A, Simsek H, Tatar G. Omeprazole and two antibiotics for Helicobacter pylori eradication. Turk J Gastroenterol 1996;7:228-32
11. Saruc M, Goksel G, Ozkaya S, Guclu F, Ozbakkaloglu B, Yuceyar H. The effect of CagA status on response to Helicobacter pylori eradication therapy. Braz J Med Biol Res 2001;34:1435-9
12. Uygun A, Ates Y, Erdil A, et al. Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. Clin Ther 1999;21:1539-48
13. Eralp Y, Dobrucali A, Bagatur N et al. A comparison of lansoprazole and omeprazole based triple combinations for the treatment of Helicobacter pylori associated gastritis and peptic ulcer. Turk J Gastroenterol 2000;11:25-9
14. Simsek I. Reinfection rate of H. pylori infection after one and two weeks triple therapy. A 17 month follow-up study. Gut 2000;47(Suppl III):A103
15. Misiewicz JJ. The Sydney system: a new classification of gastritis. Working Party Reports 1991;6:207-8
16. Malfertheiner P, Kirchner T, Kist M, et al.; Advanced Gastric Ulcer Study Group. Helicobacter pylori eradication and gastric ulcer healing - comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther 2003;17:1125-35
17. Bhasin DK, Sharma BC, Ray P, Pathak CM, Singh K. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India. Helicobacter 2000;5:84-7
18. Gisbert JP, Carpio D, Marcos S, Gisbert JL, Garcia Gravalos R, Pajares JM. One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2000;12:489-95
19. Lamouliatte H, Samoyeau R, De Mascarel A, Megraud F. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999;13:1523-30
20. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastrich triple therapy'. Aliment Pharmacol Ther 2001;15:1023-29
21. Malekzadeh R, Merat S, Derakhshan MH, et al. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003;18:13-7
22. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998;93:1432-35
23. Aydin A, Buke C, Akiner C, et al. Is sensitivity of Helicobacter pylori to clarithromycin decreasing? Turk J Gastroenterol 1998;9(Suppl 1):55
24. Kantarceken B, Yildirim B, Karincaoglu M, Aladag M, Hilmioglu F. Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000;11;141-5
25. Pamuk ON, Pamuk GE, Celik A, Uzunismail H. Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? Am J Gastroenterol 2000;95:1839-40
26. Eun CS, Han DS, Park JY, et al. Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol 2003;38:436-41
27. Hulagu S, et al. Kocaeli University Faculty of Medicine, Department of Gastroenterology. Unpublished data. 2003
28. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clinical Microbiol Infect 2002;8:388-96
29. Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomised studies. Helicobacter 2003;8:626-42
30. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-99 [summary for patients in Ann Intern Med 2002 January 1;136: I-39; PMID. 11797613]. Ann Intern Med 2002;136:13-24
31. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161:1217-20